IMTX

Immatics N.V. is a clinical-stage biopharmaceutical company focused on developing T cell receptor (TCR) based immunotherapies for cancer treatment. The company's proprietary technology platform identifies cancer-specific targets and engineers TCRs to direct patients' immune systems to detect and eliminate tumor cells. Immatics is advancing multiple TCR therapy candidates through clinical trials, targeting various solid tumors and hematological malignancies. The company combines its target discovery capabilities with adoptive cell therapy and TCR bispecifics development to create a comprehensive oncology pipeline.